A recent multicentre trial in the United Kingdom is set to determine the effectiveness of a 12-week home-based cardiac rehabilitation program, REACH-HF, for individuals suffering from heart failure with preserved ejection fraction (HFpEF). This condition often leads to significant functional limitations and diminished quality of life for patients and their caregivers.
Study Design and Methodology
The REACH-HFpEF trial employs a parallel two-group randomized controlled approach, enrolling 372 participants along with their caregivers from secondary care centers. Participants are randomly assigned to either receive the REACH-HF intervention in addition to standard care or continue with usual care alone. The study monitors outcomes at baseline, four months, and twelve months, focusing primarily on disease-specific health-related quality of life (HRQoL) using the Minnesota Living with Heart Failure questionnaire.
Comprehensive Outcome Measures
Secondary metrics include exercise capacity, psychological well-being, physical activity levels, generic HRQoL, self-management abilities, frailty status, blood biomarkers, mortality rates, hospitalizations, and serious adverse events. Caregivers’ HRQoL and burden are also assessed. A process evaluation will examine the fidelity of the intervention and adherence to the exercise regimen, while qualitative studies aim to capture facilitators’ experiences in delivering the program.
• REACH-HF may enhance patients’ quality of life compared to usual care.
• The intervention could reduce hospitalizations and mortality rates.
• Caregiver burden might decrease with patient participation in REACH-HF.
• Cost-effectiveness analysis will determine the economic viability of the program.
The trial’s registration number is ISRCTN47894539, and it has received ethical approval from the West of Scotland Research Ethics Committee. Findings are expected to be shared through peer-reviewed journals and conferences, targeting researchers, healthcare users, and policymakers.
Implementing a home-based rehabilitation program like REACH-HF could revolutionize care for HFpEF patients by providing accessible and effective support outside traditional clinical settings. If proven cost-effective, this approach may become a standard component of heart failure management, potentially improving outcomes and reducing the strain on healthcare systems. Patients and caregivers stand to benefit from enhanced quality of life and reduced healthcare costs, marking a significant advancement in the treatment of a challenging cardiovascular condition.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
